Paxman AB (B0F) Price & Analysis
B0F Stock Chart & Stats
- Day’s Range
- EUR 5.79 - EUR 5.79
- 52-Week Range
- EUR 3.78 - EUR 6.10
- Previous Close
- EUR 5.96
- Volume
- 0
- Average Volume (3M)
- 17
- Market Cap
- EUR 140.14M
- Enterprise Value
- EUR 1.06B
- Total Cash (Recent Filing)
- EUR 105.64M
- Total Debt (Recent Filing)
- EUR 12.37M
- Price to Earnings (P/E)
- ―
- Beta
- 0.22
- Next Earnings
- Nov 20, 2026
- EPS Estimate
- 0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Commercial Growth
Rapid sales growth indicates expanding adoption of Paxman’s scalp-cooling systems and stronger commercial execution. If sustained, higher revenue can broaden the installed base, increase treatment-related recurring income, and improve operating leverage as the business scales.
Recurring IBBM Utilization Growth
The sharp increase in insurance-based billing supports a more repeatable revenue model tied to patient treatments rather than only equipment placements. Higher utilization can deepen site economics, encourage broader clinic adoption, and increase recurring revenue from the installed base.
Conservative Balance Sheet
Very low leverage reduces financial risk and preserves flexibility to fund commercial expansion, product development, and customer installations without substantial debt-service pressure. A conservative capital structure also gives Paxman greater resilience if profitability or cash generation remains uneven.
Bears Say
Recent Return To Losses
The return to a net loss weakens the immediate earnings foundation despite strong revenue momentum. Near-break-even operating profit leaves limited room for cost increases or execution setbacks, while sustained losses could constrain reinvestment and reduce the durability of reported growth.
Negative Cash Generation
Negative operating and free cash flow indicate that current operations are not yet funding reinvestment and working-capital needs internally. If this persists alongside losses, Paxman may need to rely more heavily on existing liquidity or external funding to support expansion.
Neuropathy-device Regulatory Delay
The De Novo pathway delays potential commercialization of the neuropathy device and introduces greater approval uncertainty than the planned 510(k) route. Additional information or clinical-data requests could extend timing further, postponing a potentially important product and revenue opportunity.
Paxman AB News
B0F FAQ
What was Paxman AB’s price range in the past 12 months?
What is Paxman AB’s market cap?
When is Paxman AB’s upcoming earnings report date?
How were Paxman AB’s earnings last quarter?
Is Paxman AB overvalued?
Does Paxman AB pay dividends?
What is Paxman AB’s EPS estimate?
How many shares outstanding does Paxman AB have?
What happened to Paxman AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Paxman AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Paxman AB
Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed across Europe, the United States, Mexico, Japan, Oceania, various Asian regions, and both South and Central America, primarily serving cancer centers and hospitals. The company is also engaged in a research collaboration agreement with the National University Hospital in Singapore, working towards the development of a portable cooling and compression device. Established in 1996, Paxman AB (publ) is headquartered in Karlshamn, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Richard Paxman
- Employees
- 151
- Website
- www.paxman.se
- Address
- Pirgatan 13, Karlshamn, BL, 374 35, SE
Paxman AB (B0F) Earnings & Revenues
B0F Earnings Call
Earnings Call SentimentPositive
The call highlights strong commercial momentum: record quarterly sales (+40% YoY), substantial U.S. revenue growth (~+77.5% YoY), large increases in insurance-based billing (110%), improved adjusted margins (~19%), a robust order book (190 systems, 80 in U.S.), and a healthy cash position (SEK 105m). These positives are tempered by a regulatory setback for the neuropathy device (shift to De Novo with an 8–12 month review window), increased operating and CIPN-related costs (OpEx up ~SEK 6m q/q; CIPN costs up ~30%), and a slower near-term U.S. rollout for CIPN. Overall, company fundamentals and commercial traction are strong and appear to outweigh the regulatory and cost challenges, but the De Novo timeline introduces meaningful near-term uncertainty for the new product launch.
View all DE:B0F earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 4 | 3 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 12 | 0 | 0 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:SEZISenzime AB | ||
| SE:XVIVOXvivo Perfusion AB | ||
| SE:BACTI.BBactiguard Holding AB | ||
| SE:BRAINBrainCool AB | ||
| SE:SEDANASedana Medical AB |